Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
20 participants
INTERVENTIONAL
2010-12-31
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain
NCT01675050
Comparison of Chlorpromazine or Pentobarbital Premedications for Pediatric Imaging Procedures
NCT04350528
Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant With Colic Not Responding to Conventional Treatment
NCT01309009
Gender Difference in Response to Caffeine in Children and Adolescents
NCT02119416
Safety Evaluation of Propofol Sedation for Magnetic Resonance Imaging in Pediatric Patients
NCT04455776
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cyproheptadine
Cross-over study
Cyproheptadine
0,25mg/kg/day orally in 2 doses per day (2mg/5 ml)for 1 month
Sugar pill
Cross-over study
Sugar pill
liquid placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cyproheptadine
0,25mg/kg/day orally in 2 doses per day (2mg/5 ml)for 1 month
Sugar pill
liquid placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* failure to thrive
Exclusion Criteria
* Medication interacting with Cyproheptadine
* Prematurity under 36 weeks of gestation
* Neurologic impairment
* underlying organic disease
2 Years
4 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. Justine's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ste-Justine University Health Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ste-Justine University Health Center
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Cypro-24
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.